Biotech BioDelivery Sciences has won a patent dispute: shares have risen in price
BioDelivery Sciences International Inc. (BDSI) has won a critical patent dispute, which will keep sales of painkillers high. After the court’s decision, the quotations of BioDelivery Sciences increased by more than 26% at the auction on December 20. The auction ended on December 29 at $3.3.
BioDelivery Sciences, specializing in pain relief and neurological therapy, won a patent dispute related to Belbuca. The decision of a trial judge in Delaware will not allow Alvogen to sell a nonproprietary version of Belbuca owned by BioDelivery Sciences. Note that the patents expire only in 2032. Belbuca is an opioid drug that relieves chronic long-term pain.
The drug was the company’s sales leader in the third quarter and generated revenue of $36.9 million, which is 6.3% more year-on-year. Another part of BioDelivery Sciences’ revenue comes from Symproic, which brought in $4.1 million in sales and $20,000 in royalty revenue last year. Thus, the preservation of the patent rights to Belbuca is a crucial factor for maintaining the high payment of BioDelivery Sciences in the coming years.
There were twenty-one thousand prescriptions for this drug in the third quarter, 7.7% more than a year earlier.
BioDelivery Sciences International Inc. has increased revenue for five years and net profit for three years. BioDelivery also improved its profit margin to 27% in the third quarter. Note that in addition to Belbuca and Symproic, BioDelivery Sciences has a migraine medicine Elyxyb, which it received after acquiring Dr. Reddy’s Laboratories this year. The launch of the drug for the first quarter of 2022. According to the company’s forecast, sales of Elyxyb will be able to provide from $ 300 million to $ 500 million per year.
